Autoimmune disorder therapeutic - Boehringer Ingelheim
Alternative Names: Small molecule therapeutic - Boehringer IngelheimLatest Information Update: 09 Jan 2026
At a glance
- Originator Kyowa Kirin
- Developer Boehringer Ingelheim
- Class Immunotherapies; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Autoimmune disorders